First Trust Advisors
TCRR

First Trust Advisors’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

First Trust Advisors’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-27,999
Closed -$430K – 2524
2020
Q2 		$430K Buy
27,999
+2,022
+8% +$23.3K ﹤0.01% 2068
2020
Q1 		$201K Sell
25,977
-5,038
-16% -$61.7K ﹤0.01% 2203
2019
Q4 		$443K Sell
31,015
-517
-2% -$7.99K ﹤0.01% 2152
2019
Q3 		$474K Buy
+31,532
New +$491K ﹤0.01% 2133

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

First Trust Advisors's TCRR Position: Q3 2020 in Review

First Trust Advisors sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q3 2020, closing a stake of 27,999 shares — an estimated $430K sold.

First Trust Advisors first reported a position in TCRR in Q3 2019 and held it in 4 quarters. The position peaked at $474K in Q3 2019. 82 funds tracked by Wall St. Rank hold TCRR as of Q3 2020.

  • First Trust Advisors reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • First Trust Advisors sold 27,999 TCR2 Therapeutics Inc. Common Stock shares in Q3 2020, an estimated $430K.
  • First Trust Advisors first reported a position in TCR2 Therapeutics Inc. Common Stock in Q3 2019 and held it in 4 quarters.
  • First Trust Advisors's TCR2 Therapeutics Inc. Common Stock position peaked at $474K in Q3 2019.
  • 82 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q3 2020.

Based on First Trust Advisors's 13F filing for Q3 2020, filed 5 Nov 2020.